Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 07:34 am
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 47,473.09 million compared to KRW 49,358.13 million a year ago. Net income was KRW 2,427.93 million compared to KRW 5,101.24 million a year ago. Basic earnings per share from continuing operations was KRW 89 compared to KRW 185 a year ago. Basic earnings per share was KRW 89 compared to KRW 185 a year ago.
For the nine months, sales was KRW 11,234.58 million compared to KRW 10,773.53 million a year ago. Net income was KRW 4,469.13 million compared to KRW 10,635.15 million a year ago. Basic earnings per share from continuing operations was KRW 164 compared to KRW 385 a year ago. Basic earnings per share was KRW 164 compared to KRW 385 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 
